The FDA has approved Ozempic, a medication manufactured by Dutch company Novo Nordisk, for treating type 2 diabetes. Many healthcare providers also prescribe Ozempic to their patients for weight management purposes. This is because the medication’s active ingredient, semaglutide, has been approved for weight loss treatments. As the drug has increased in popularity for weight loss, so do cases of adverse reactions to the drug. Specifically, patients prescribed drugs like Ozempic, Wegovy, Mounjaro and Trulicity have suffered gastrointestinal diseases, cancer, and even deaths related to the use of Ozempic. Get updates about the Ozempic lawsuit in 2024 below.
Lawsuits for Ozempic Side Effects
While common side effects of using Ozempic include nausea and vomiting, studies have shown an increased risk of gastrointestinal issues and gallbladder diseases when taking Ozempic for weight loss. Ozempic’s manufacturer added a warning label to the drug in September 2023, warning patients of the increased risk of gallbladder disease when using the drug.
One of the most severe side effects of taking Ozempic for weight loss is gastroparesis. Gastroparesis is a paralysis of the stomach where the nerves and muscles in the stomach weaken, making digesting food difficult. Intestinal blockages and obstructions prohibit food from adequately moving through the digestive tract. This leads to chronic nausea and diarrhea, and there’s no cure. In severe cases, it can be life-threatening.
Ozempic Lawsuit Updates: March 2024
The first lawsuit against Ozempic manufacturer Novo Nordisk was in August 2023. The suit alleged that Novo Nordisk failed to warn patients of the potential risks for gastroparesis, ileus, and gallbladder disease when taking the drug. There have been several significant updates in the case over the last seven months. On February 4, 2024, The U.S. Judicial Panel on Multidistrict Litigation (MDL) ordered that all current Ozempic lawsuits in federal court be centralized in the Eastern District of Pennsylvania with Judge Gene E.K. Pratter presiding. The ruling has made the case against Ozempic and other GLP-1 receptor agonist drugs, such as Wegovy, Mounjaro, and Trulicity, for failing to warn users about the risk of gastroparesis. At the time of publication, there were over 55 cases included in the MDL. Many more patients will likely come forward in the coming months.
What is the New Lawsuit Against Ozempic?
Lawsuits against Ozempic were consolidated into a Multidistrict Litigation (MDL) in February 2024. MDLs consolidate individual lawsuits with common claims to collect pretrial evidence and attend hearings. However, each case is settled separately. Contact experienced MDL tort attorneys, like our team at Michael Brady Lynch Law Firm, for more information about how the Ozempic lawsuit will play out in court.
How Long Will It Take to Settle the Ozempic Lawsuit?
The MDL against Ozempic is in the early stages of litigation. It could take a few months or several years to receive a settlement. If you’ve been diagnosed with gastroparesis after taking Ozempic, contact an attorney to see if you’re eligible to make a claim.
How Much Can I Get from the Ozempic Lawsuit in 2024?
Compensation may cover lost wages, medical expenses, emotional distress, and pain and suffering. The compensation you may be entitled to will depend on the unique circumstances of your case and the extent of your injuries.
Ozempic Lawsuit Eligibility
You may be eligible to file a claim if you took Ozempic, Wegovy, Mounjaro, or Trulicity and were diagnosed with gastroparesis. The Michael Brady Lynch Law Firm is dedicated to helping you receive damages for your injuries or a loved one’s Ozempic-related death. Call our office at 888-585-5970 to discuss your case to see if you qualify.